-
广东美丽康荣获美国国家科学基金会（NSF）GMP认证
广东美丽康凭借其卓越的产品品质和生产管理水平，成功获得了科研创新资助机构美国国家科学基金会（NSF）颁发的良好生产规范（GMP）认证。这一荣誉不仅标志着广东美丽康在保健品生产领域的领先地位，也体现了其对产品质量和消费者健康的严格把控。
넶178 2024-05-11 -
B&H Case Study: Helping B-Complex Tablets Enter the Southeast Asia Market in Just Six Months
As the global nutrition and health market undergoes structural transformation, Southeast Asia — powered by population growth and rising consumer demand — has emerged as a new blue ocean for China’s health supplement exports. For many OEM manufacturers, the competition now centers on one question: how to complete product initiation, formulation development, regulatory filing, and market entry in the shortest possible time.
넶0 2025-12-01 -
广东美丽康（B&H）创新OEM案例｜复合片剂出口东南亚，六个月打造合规快速通道
在全球营养健康市场格局重塑的当下，东南亚凭借人口红利与消费升级，成为中国保健品出口的新蓝海。如何在最短时间内完成产品立项、配方研发、法规备案与市场入驻，成为各大OEM代工企业竞争的焦点。
近日，广东美丽康（B&H）公布了一项成功案例：其协助一家国际品牌客户在六个月内完成复合片剂出口东南亚的全流程，实现从研发到上架的高效转化，成为业内典型的OEM出口案例。넶0 2025-12-01 -
B&H Case Study: Supplement Tablets Enter Southeast Asia Market within Six Months
In recent years, the nutrition and health supplement market in Southeast Asia has grown rapidly. Demand for supplement tablets in countries such as Vietnam, Thailand, and Indonesia continues to rise. Facing massive consumer potential and complex regulatory diversity, many health brands share the same challenge — how to enter their target markets quickly, compliantly, and with minimal risk.
넶0 2025-12-01 -
广东美丽康（B&H）助力客户复合片剂快速打入东南亚市场，实现OEM出口新突破
近年来，东南亚营养健康品市场增长迅猛，越南、泰国、印尼等国的膳食补充剂（supplement tablets）需求持续攀升。面对庞大的消费潜力与多样化的法规要求，如何让产品“快速、合规、低风险”地进入目标市场，成为众多健康品牌共同的挑战。
在这一背景下，广东美丽康（B&H）凭借其在保健品OEM出口与复合片剂生产研发领域的专业优势，帮助一家跨境品牌客户仅用六个月时间，就成功完成产品配方开发、注册备案与首批出口东南亚上市，实现从“概念产品”到“市场落地”的高效转化。넶0 2025-12-01 -
B&H: Integrating Regulatory Compliance into Supplement Formulation Development
In recent years, regulatory authorities around the world have been tightening their scrutiny of supplement formulation and health claims. For example, the U.S. FDA has become more rigorous with its NDI (New Dietary Ingredient) filings, the European EFSA has increased its requirements for the functional validation of botanical extracts, and Australia’s TGA explicitly mandates that any “therapeutic claims” appearing on product labels must be backed by scientific evidence.
넶0 2025-12-01
